MUCCINI, CAMILLA
 Distribuzione geografica
Continente #
EU - Europa 1.855
NA - Nord America 1.625
AS - Asia 1.412
SA - Sud America 235
Continente sconosciuto - Info sul continente non disponibili 148
AF - Africa 63
OC - Oceania 14
Totale 5.352
Nazione #
US - Stati Uniti d'America 1.533
RU - Federazione Russa 1.066
CN - Cina 473
SG - Singapore 444
IT - Italia 269
BR - Brasile 185
HK - Hong Kong 128
VN - Vietnam 127
DE - Germania 119
SE - Svezia 115
GB - Regno Unito 66
FR - Francia 65
BD - Bangladesh 54
CA - Canada 48
FI - Finlandia 40
IN - India 35
JP - Giappone 23
ES - Italia 22
ZA - Sudafrica 22
PL - Polonia 20
MX - Messico 19
AT - Austria 17
NL - Olanda 16
AR - Argentina 15
ID - Indonesia 15
TR - Turchia 15
AE - Emirati Arabi Uniti 13
AU - Australia 13
IQ - Iraq 13
LT - Lituania 12
PK - Pakistan 12
NG - Nigeria 10
PH - Filippine 9
VE - Venezuela 8
BE - Belgio 7
CH - Svizzera 7
EC - Ecuador 7
PE - Perù 7
TN - Tunisia 7
CO - Colombia 6
GH - Ghana 6
MY - Malesia 6
CR - Costa Rica 5
JM - Giamaica 5
SA - Arabia Saudita 5
UZ - Uzbekistan 5
CL - Cile 4
IR - Iran 4
PS - Palestinian Territory 4
CY - Cipro 3
DO - Repubblica Dominicana 3
ET - Etiopia 3
HN - Honduras 3
KE - Kenya 3
MA - Marocco 3
MD - Moldavia 3
OM - Oman 3
TH - Thailandia 3
AZ - Azerbaigian 2
BH - Bahrain 2
IE - Irlanda 2
IL - Israele 2
JO - Giordania 2
KR - Corea 2
MZ - Mozambico 2
NP - Nepal 2
SV - El Salvador 2
TZ - Tanzania 2
UG - Uganda 2
UY - Uruguay 2
AL - Albania 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BM - Bermuda 1
BO - Bolivia 1
BZ - Belize 1
CI - Costa d'Avorio 1
CZ - Repubblica Ceca 1
DZ - Algeria 1
EE - Estonia 1
EG - Egitto 1
EU - Europa 1
GR - Grecia 1
GT - Guatemala 1
HR - Croazia 1
KW - Kuwait 1
KZ - Kazakistan 1
LB - Libano 1
LK - Sri Lanka 1
MT - Malta 1
NI - Nicaragua 1
PA - Panama 1
RO - Romania 1
SY - Repubblica araba siriana 1
TT - Trinidad e Tobago 1
TV - Tuvalu 1
UA - Ucraina 1
Totale 5.205
Città #
Singapore 259
Ashburn 209
Moscow 192
Dallas 185
San Jose 158
Hong Kong 124
New York 118
Shanghai 92
Beijing 86
Council Bluffs 82
Munich 54
Ho Chi Minh City 53
Hefei 49
Milan 47
Lauterbourg 44
Los Angeles 43
Rome 39
Orem 34
Boardman 33
Hanoi 33
Helsinki 27
Santa Clara 25
São Paulo 25
Denver 24
Nuremberg 23
Lawrence 22
Princeton 22
Tokyo 22
Montreal 20
Warsaw 20
Houston 18
Omaha 18
Atlanta 16
Poplar 16
Johannesburg 15
London 15
Chennai 13
Frankfurt am Main 12
Seattle 12
Washington 12
Chicago 11
Toronto 11
Boston 10
Brooklyn 10
Guangzhou 10
Phoenix 10
Manchester 9
Mexico City 9
Ankara 8
Pietra Ligure 8
Rio de Janeiro 8
Sharjah 8
Stockholm 8
Vienna 8
Falkenstein 7
Accra 6
Amsterdam 6
Baghdad 6
Barnet 6
Belo Horizonte 6
Cesano Boscone 6
Da Nang 6
Lagos 6
Madrid 6
Melbourne 6
New Delhi 6
San Francisco 6
Shenzhen 6
Turku 6
Brussels 5
Buffalo 5
Hangzhou 5
Lahore 5
Lappeenranta 5
Las Vegas 5
Lima 5
Quezon City 5
Vittoria 5
Catania 4
Charlotte 4
Columbus 4
Hải Dương 4
Karachi 4
Monsummano Terme 4
Naples 4
Ottawa 4
Pune 4
Romagnano Sesia 4
St Louis 4
Sydney 4
Tashkent 4
Vauderens 4
Angera 3
Basra 3
Brescia 3
Buenos Aires 3
Cambridge 3
Chisinau 3
City of London 3
Curitiba 3
Totale 2.655
Nome #
Evaluation of HIV reservoir in specific populations: people with a multi-drug resistant virus or a viral coinfection 311
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors 212
Meningococcus B Vaccination Effectiveness Against Neisseria gonorrhoeae Infection in People Living With HIV: A Case-Control Study 197
Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 184
High Risk of Secondary Infections Following Thrombotic Complications in Patients With COVID-19 179
Candidemia in COVID-19 patients: incidence and characteristics in a prospective cohort compared to historical non-COVID-19 controls 152
A case of breakthrough mpox infection in an individual non-responder to MVA-BN vaccination 135
Publisher Correction: Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 (Scientific Reports, (2020), 10, 1, (21291), 10.1038/s41598-020-78039-1) 130
Analytical treatment interruption in chronic HIV-1 infection: Time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study) 123
Association of high-risk sexual behaviours with sexually transmitted infections among men who have sex with men living with HIV 119
Dynamics of HIV-1 POL antibodies after ART in chronic HIV-1 infection 117
Achieving virological control in pan-resistant HIV-1 infection: A case series 115
Analysis of the faecal microbiome during analytical treatment interruption in people with chronic HIV infection and long-lasting virological suppression (APACHE study) 115
SARS-CoV-2 IgG/IgM Rapid Test as a Diagnostic Tool in Hospitalized Patients and Healthcare Workers, at a large Teaching Hospital in northern Italy, during the 2020 COVID-19 Pandemic 115
Treatment success of rescue regimens after dual therapy failure in people living with HIV in a real-life setting 115
Risk of Cardiovascular Diseases or Mortality in People with Higher Values of HIV-1 DNA 110
Changes in homeostatic model assessment for insulin resistance (HOMA-IR) index in treated HIV-1 infected people on virological suppression who switched to a different antiretroviral regimen 108
Brief Report: Association Between Low HIV-1 DNA and Western Blot Reactivity to HIV-1 Pol in Chronically Infected Individuals 107
Serum IgG1 and IgG4 could contribute to partial control of viral rebound in chronically HIV-1-infected patients 107
One Year of Long-Acting Cabotegravir and Rilpivirine in People With Human Immunodeficiency Virus and Long Exposure to Antiretroviral Therapy: Data From the SCohoLART Study 105
Increasing incidence and prevalence of metabolic syndrome in people living with HIV during the COVID-19 pandemic 101
A four-drug combination oral tablet of darunavir, cobicistat, emtricitabine, and tenofovir alafenamide for the treatment of HIV-1 infection in adults 100
Impact of predicted HLA class I immunopeptidome on viral reservoir in a cohort of people living with HIV in Italy 100
Two-fold increased risk of cardiovascular events in people with MDR HIV: a matched cohort analysis with data from the PRESTIGIO registry 98
Association between low levels of HIV-1 DNA and HLA class I molecules in chronic HIV-1 infection 97
Challenging management of a post-coronavirus disease 2019 invasive Aspergillus sinusitis in a person living with HIV 96
Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium 95
Efficacy and Safety Profile of Fostemsavir for the Treatment of People with Human Immunodeficiency Virus-1 (HIV-1): Current Evidence and Place in Therapy 93
Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium 91
Outcomes after a virological failure to first-line second-generation INSTI-based therapy in a real-life setting 90
Doravirine associated with greater LDL cholesterol reduction in people with HIV switching antiretroviral regimens 89
Increasing trend of transmitted integrase inhibitor resistance in a cohort of antiretroviral therapy-naive people living with HIV 89
All-Cause Mortality in People With Four-Class Drug-Resistant Human Immunodeficiency Virus: A Matched Cohort Analysis With Data From the PRESTIGIO Registry 88
Cancer incidence in people with HIV in Italy: Comparison of the ICONA COHORT with general population data 87
Anti-HIV antibodies are representative of the latent reservoir but do not correlate with viral control in people with long-lasting virological suppression undergoing analytical treatment interruption (APACHE study) 87
Should we expect weight changes in people with HIV and a reported weight gain only by switching antiretroviral therapy? 86
Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients 83
Cerebrospinal fluid viral replication and burden of resistance in three HIV-1-infected people taking Ibalizumab with multiple drug class-wide resistance 77
Western blot in treated people with HIV-1 chronic infection: frequency of negative HIV-1 pol genes 77
Residual viremia in HIV-infected patients who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor based regimen 71
Subclinical atherosclerosis as detected by carotid ultrasound and associations with cardiac and HIV-specific risk factors; the Archi-Prevaleat project 70
Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents 68
Homeostatic model assessment for insulin resistance index trajectories in HIV-infected patients treated with different first-line antiretroviral regimens 67
Persistence of CXCR4-tropic virus in people living with four-class drug-resistant HIV and its clinical impact in the modern antiretroviral era 66
HIV Pol: does it offer therapeutic targets for HIV? 61
Recent abacavir use and incident cardiovascular disease in contemporary-treated people with HIV 60
Exercise ECG for coronary artery disease screening in people living with HIV: The cordis STUDY 60
Immune activation, inflammation and HIV DNA after 96 weeks of ATV/r monotherapy: A MODAt substudy 56
Integrase Strand Transfer Inhibitor Use and Cancer Incidence in a Large Cohort Setting 49
People with four-class drug-resistant HIV-1 may have low levels of intact DNA 48
Pharmacokinetic evaluation of bictegravir + emtricitabine + tenofovir alafenamide in HIV treatment 29
Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment: Efficacy and Tolerability in Clinical Practice 20
User-reported outcomes of long-acting injectable PrEP with Cabotegravir: Real-world experience from Milan 8
HIV cure-related research: where we stand and where we go 6
Safety, Tolerability, and Metabolic Effects of Long-Acting Cabotegravir and Rilpivirine in HIV Care: A Comprehensive Review 6
Cardiometabolic complications in children and adolescents with HIV on antiretroviral therapy 5
Evaluating long-acting injectable HIV treatment: an update on cabotegravir and rilpivirine 5
Highlighting advances on clinical management of pediatric HIV 4
Improvement in high-density lipoprotein cholesterol in people with HIV who switched from a tenofovir alafenamide-containing regimen to cabotegravir plus rilpivirine 4
Time to HIV viral rebound and frequency of post-treatment control after analytical interruption of antiretroviral therapy: an individual data-based meta-analysis of 24 prospective studies 3
A neural-network approach for predicting time to cardiovascular diseases in HIV patients based on real-world data 3
Are glucagon-like peptide 1 receptor agonists effective in decreasing body weight and body mass index in people living with diabetes and HIV? 3
Totale 5.352
Categoria #
all - tutte 23.938
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.938


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202249 0 0 0 8 1 6 4 10 8 3 2 7
2022/2023202 52 44 11 3 8 18 25 22 5 2 6 6
2023/2024428 14 16 79 30 49 71 41 38 3 16 15 56
2024/2025877 66 28 19 33 79 90 120 109 90 49 59 135
2025/20263.482 245 187 220 388 313 129 282 292 927 212 180 107
2026/2027293 163 130 0 0 0 0 0 0 0 0 0 0
Totale 5.352